Natural disease history of the D2‐mdx mouse model for Duchenne muscular dystrophy

Abstract

The C57BL/10ScSn‐ Dmd mdx /J (BL10 ‐mdx ) mouse has been the most commonly used model for Duchenne muscular dystrophy (DMD) for decades. Their muscle dysfunction and pathology is, however, less severe than in patients with DMD, which complicates preclinical studies. Recent discoveries indicate that disease severity is exacerbated when muscular dystrophy mouse models are generated on a DBA2/J genetic background. Knowledge on the natural history of animal models is pivotal for high‐quality preclinical testing. However, for BL10 ‐mdx mice on a DBA2/J background (D2 ‐mdx ), limited data are available. We addressed this gap in the natural history knowledge. First, we compared histopathological aspects in skeletal muscles of young D2 ‐mdx , BL10 ‐mdx , and wild‐type mice. Pathology was more pronounced in D2 ‐mdx mice and differed in severity between muscles within individuals. Secondly, we subjected D2‐ mdx mice to a functional test regime for 34 weeks and identified that female D2‐ mdx mice outperform severely impaired males, making females less useful for functional preclinical studies. Direct comparisons between 10‐ and 34‐wk‐old D2 ‐mdx mice revealed that disease pathology ameliorates with age. Heart pathology was progressive, with some features already evident at a young age. This natural history study of the D2‐ mdx mouse will be instrumental for experimental design of future preclinical studies.—Van Putten, M., Putker, K., Overzier, M., Adamzek, W. A., Pasteuning‐Vuhman, S., Plomp, J. J., Aartsma‐Rus, A. Natural disease history of the D2‐ mdx mouse model for Duchenne muscular dystrophy. FASEB J. 33, 8110–8124 (2019). www.fasebj.org

References 38

1. 1.

   Mendell J. R., Rodino-Klapac L. R., Sahenk Z., Roush K., Bird L., Lowes L. P., Alfano L., Gomez A. M., Lewis S., Kota J., Malik V., Shontz K., Walker C. M., Flanigan K. M., Corridore M., Kean J. R., Allen H. D., Shilling C., Melia K. R., Sazani P., Saoud J. B., Kaye E. M.; Eteplirsen Study Group (2013 ) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637–647

   Not in our library10.1002/ana.23982

2. 2.

   Moat S. J., Bradley D. M., Salmon R., Clarke A., Hartley L. (2013 ) Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur. J. Hum. Genet. 21, 1049–1053

   Not in our library10.1038/ejhg.2012.301

3. 3.

   Straub V., Balabanov P., Bushby K., Ensini M., Goemans N., De Luca A., Pereda A., Hemmings R., Campion G., Kaye E., Arechavala-Gomeza V., Goyenvalle A., Niks E., Veldhuizen O., Furlong P., Stoyanova-Beninska V., Wood M. J., Johnson A., Mercuri E., Muntoni F., Sepodes B., Haas M., Vroom E., Aartsma-Rus A. (2016 ) Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol. 15, 882–890

   Not in our library10.1016/s1474-4422(16)30035-7

4. 4.

   Emery A. E. (2002 ) The muscular dystrophies. Lancet 359, 687–695

   Not in our library10.1016/s0140-6736(02)07815-7

5. 5.

   Kim S., Campbell K. A., Fox D. J., Matthews D. J., Valdez R.; MD STARnet (2015 ) Corticosteroid treatments in males with Duchenne muscular dystrophy: treatment duration and time to loss of ambulation. J. Child Neurol. 30, 1275–1280

   Not in our library10.1177/0883073814558120

6. 6.

   Moxley R. T. III, Pandya S., Ciafaloni E., Fox D. J., Campbell K. (2010 ) Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J. Child Neurol. 25, 1116–1129

   Not in our library10.1177/0883073810371004

7. 7.

   Emery A. E. H., Muntoni F., Quinlivan R. C. M. (2015 ) Duchenne Muscular Dystrophy, Oxford University Press, Oxford, United Kingdom

   Not in our library

8. 8.

   Bladen C. L., Salgado D., Monges S., Foncuberta M. E., Kekou K., Kosma K., Dawkins H., Lamont L., Roy A. J., Chamova T., Guergueltcheva V., Chan S., Korngut L., Campbell C., Dai Y., Wang J., Barišić N., Brabec P., Lahdetie J., Walter M. C., Schreiber-Katz O., Karcagi V., Garami M., Viswanathan V., Bayat F., Buccella F., Kimura E., Koeks Z., van den Bergen J. C., Rodrigues M., Roxburgh R., Lusakowska A., Kostera-Pruszczyk A., Zimowski J., Santos R., Neagu E., Artemieva S., Rasic V. M., Vojinovic D., Posada M., Bloetzer C., Jeannet P. Y., Joncourt F., Díaz-Manera J., Gallardo E., Karaduman A. A., Topaloğlu H., El Sherif R., Stringer A., Shatillo A. V., Martin A. S., Peay H. L., Bellgard M. I., Kirschner J., Flanigan K. M., Straub V., Bushby K., Verschuuren J., Aartsma-Rus A., Béroud C., Lochmüller H. (2015 ) The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395–402

   Not in our library10.1002/humu.22758

9. 9.

   Hoffman E. P., Brown R. H. Jr., Kunkel L. M. (1987 ) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928

   Not in our library10.1016/0092-8674(87)90579-4

10. 10.

    Gissel H. (2005 ) The role of Ca2+ in muscle cell damage. Ann. N. Y. Acad. Sci. 1066, 166–180

    Not in our library10.1196/annals.1363.013

11. 11.

    Klingler W., Jurkat-Rott K., Lehmann-Horn F., Schleip R. (2012 ) The role of fibrosis in Duchenne muscular dystrophy. Acta Myol. 31, 184–195

    Not in our library

12. 12.

    Wallace G. Q., McNally E. M. (2009 ) Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu. Rev. Physiol. 71, 37–57

    Not in our library10.1146/annurev.physiol.010908.163216

13. 13.

    Sicinski P., Geng Y., Ryder-Cook A. S., Barnard E. A., Darlison M. G., Barnard P. J. (1989 ) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578–1580

    Not in our library10.1126/science.2662404

14. 14.

    DiMario J. X., Uzman A., Strohman R. C. (1991 ) Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle. Dev. Biol. 148, 314–321

    Not in our library10.1016/0012-1606(91)90340-9

15. 15.

    Boldrin L., Zammit P. S., Morgan J. E. (2015 ) Satellite cells from dystrophic muscle retain regenerative capacity. Stem Cell Res. (Amst.) 14, 20–29

    Not in our library10.1016/j.scr.2014.10.007

16. 16.

    Grounds M. D., Radley H. G., Lynch G. S., Nagaraju K., De Luca A. (2008 ) Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol. Dis. 31, 1–19

    Not in our library10.1016/j.nbd.2008.03.008

17. 17.

    De Luca A. (2012 ) Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview. Acta Myol. 31, 40–47

    Not in our library

18. 18.

    Fukada S., Morikawa D., Yamamoto Y., Yoshida T., Sumie N., Yamaguchi M., Ito T., Miyagoe-Suzuki Y., Takeda S., Tsujikawa K., Yamamoto H. (2010 ) Genetic background affects properties of satellite cells and mdx phenotypes. Am. J. Pathol. 176, 2414–2424

    Not in our library10.2353/ajpath.2010.090887

19. 19.

    Coley W. D., Bogdanik L., Vila M. C., Yu Q., Van Der Meulen J. H., Rayavarapu S., Novak J. S., Nearing M., Quinn J. L., Saunders A., Dolan C., Andrews W., Lammert C., Austin A., Partridge T. A., Cox G. A., Lutz C., Nagaraju K. (2016 ) Effect of genetic background on the dystrophic phenotype in mdx mice. Hum. Mol. Genet. 25, 130–145

    Not in our library10.1093/hmg/ddv460

20. 20.

    Heydemann A., Ceco E., Lim J. E., Hadhazy M., Ryder P., Moran J. L., Beier D. R., Palmer A. A., McNally E. M. (2009 ) Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J. Clin. Invest. 119, 3703–3712

    Not in our library10.1172/jci39845

21. 21.

    Flanigan K. M., Ceco E., Lamar K. M., Kaminoh Y., Dunn D. M., Mendell J. R., King W. M., Pestronk A., Florence J. M., Mathews K. D., Finkel R. S., Swoboda K. J., Gappmaier E., Howard M. T., Day J. W., McDonald C., McNally E. M., Weiss R. B.; United Dystrophinopathy Project (2013 ) LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann. Neurol. 73, 481–488

    Not in our library10.1002/ana.23819

22. 22.

    Van den Bergen J. C., Hiller M., Böhringer S., Vijfhuizen L., Ginjaar H. B., Chaouch A., Bushby K., Straub V., Scoto M., Cirak S., Humbertclaude V., Claustres M., Scotton C., Passarelli C., Lochmüller H., Muntoni F., Tuffery-Giraud S., Ferlini A., Aartsma-Rus A. M., Verschuuren J. J., ’t Hoen P. A., Spitali P. (2015 ) Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J. Neurol. Neurosurg. Psychiatry 86, 1060–1065

    Not in our library10.1136/jnnp-2014-308409

23. 23.

    Rodrigues M., Echigoya Y., Maruyama R., Lim K. R., Fukada S. I., Yokota T. (2016 ) Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background. Sci. Rep. 6, 38371

    Not in our library10.1038/srep38371

24. 24.

    Roberts N. W., Holley-Cuthrell J., Gonzalez-Vega M., Mull A. J., Heydemann A. (2015 ) Biochemical and functional comparisons of mdx and Sgcg(-/-) muscular dystrophy mouse models. BioMed Res. Int. 2015, 131436

    Not in our library10.1155/2015/131436

25. 25.

    Vohra R., Batra A., Forbes S. C., Vandenborne K., Walter G. A. (2017 ) Magnetic resonance monitoring of disease progression in mdx mice on different genetic backgrounds. Am. J. Pathol. 187, 2060–2070

    Not in our library10.1016/j.ajpath.2017.05.010

26. 26.

    Hakim C. H., Wasala N. B., Pan X., Kodippili K., Yue Y., Zhang K., Yao G., Haffner B., Duan S. X., Ramos J., Schneider J. S., Yang N. N., Chamberlain J. S., Duan D. (2017 ) A five-repeat micro-dystrophin gene ameliorated dystrophic phenotype in the severe DBA/2J-mdx model of Duchenne muscular dystrophy. Mol. Ther. Methods Clin. Dev. 6, 216–230

    Not in our library10.1016/j.omtm.2017.06.006

27. 27.

    Gordish-Dressman H., Willmann R., Dalle Pazze L., Kreibich A., van Putten M., Heydemann A., Bogdanik L., Lutz C., Davies K., Demonbruen A. R., Duan D., Elsey D., Fukada S. I., Girgenrath M., Patrick Gonzalez J., Grounds M. D., Nichols A., Partridge T., Passini M., Sanarica F., Schnell F. J., Wells D. J., Yokota T., Young C. S., Zhong Z., Spurney C., Spencer M., De Luca A., Nagaraju K., Aartsma-Rus A. (2018 ) “Of mice and measures”: a Project to improve how we advance Duchenne muscular dystrophy therapies to the clinic. J. Neuromuscul. Dis. 5, 407–417

    Not in our library10.3233/jnd-180324

28. 28.

    Aartsma-Rus A., van Putten M. (2014 ) Assessing functional performance in the mdx mouse model. J. Vis. Exp.

    Not in our library10.3791/51303

29. 29.

    Van der Pijl E. M., van Putten M., Niks E. H., Verschuuren J. J., Aartsma-Rus A., Plomp J. J. (2016 ) Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. Eur. J. Neurosci. 43, 1623–1635

    Not in our library10.1111/ejn.13249

30. 30.

    Ruijter J. M., Ramakers C., Hoogaars W. M., Karlen Y., Bakker O., van den Hoff M. J., Moorman A. F. (2009 ) Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 37, e45

    Not in our library10.1093/nar/gkp045

31. 31.

    Aherrahrou Z., Doehring L. C., Kaczmarek P. M., Liptau H., Ehlers E. M., Pomarino A., Wrobel S., Götz A., Mayer B., Erdmann J., Schunkert H. (2007 ) Ultrafine mapping of Dyscalc1 to an 80-kb chromosomal segment on chromosome 7 in mice susceptible for dystrophic calcification. Physiol. Genomics 28, 203–212

    Not in our library10.1152/physiolgenomics.00133.2006

32. 32.

    Meng H., Vera I., Che N., Wang X., Wang S. S., Ingram-Drake L., Schadt E. E., Drake T. A., Lusis A. J. (2007 ) Identification of Abcc6 as the major causal gene for dystrophic cardiac calcification in mice through integrative genomics. Proc. Natl. Acad. Sci. USA 104, 4530–4535

    Not in our library10.1073/pnas.0607620104

33. 33.

    Swaggart K. A., Demonbreun A. R., Vo A. H., Swanson K. E., Kim E. Y., Fahrenbach J. P., Holley-Cuthrell J., Eskin A., Chen Z., Squire K., Heydemann A., Palmer A. A., Nelson S. F., McNally E. M. (2014 ) Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. Proc. Natl. Acad. Sci. USA 111, 6004–6009

    Not in our library10.1073/pnas.1324242111

34. 34.

    Weiss R. B., Vieland V. J., Dunn D. M., Kaminoh Y., Flanigan K. M.; United Dystrophinopathy Project (2018 ) Long-range genomic regulators of THBS1 and LTBP4 modify disease severity in duchenne muscular dystrophy. Ann. Neurol. 84, 234–245

    Not in our library10.1002/ana.25283

35. 35.

    Hourdé C., Joanne P., Noirez P., Agbulut O., Butler-Browne G., Ferry A. (2013 ) Protective effect of female gender-related factors on muscle force-generating capacity and fragility in the dystrophic mdx mouse. Muscle Nerve 48, 68–75

    Not in our library10.1002/mus.23700

36. 36.

    Hakim C. H., Duan D. (2012 ) Gender differences in contractile and passive properties of mdx extensor digitorum longus muscle. Muscle Nerve 45, 250–256

    Not in our library10.1002/mus.22275

37. 37.

    Pasteuning-Vuhman S., Putker K., Tanganyika-de Winter C. L., Boertje-van der Meulen J. W., van Vliet L., Overzier M., Plomp J. J., Aartsma-Rus A., van Putten M. (2017 ) Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F. PLoS One 12, e0182704

    Not in our library10.1371/journal.pone.0182704

38. 38.

    Van der Pijl E. M., van Putten M., Niks E. H., Verschuuren J. J. G. M., Aartsma-Rus A., Plomp J. J. (2018 ) Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice. Neuromuscul. Disord. 28, 427–442

    Not in our library10.1016/j.nmd.2018.02.013

Cited by papers we hold 4

• Natural history study and statistical modeling of disease progression in a preclinical model of myotubular myopathy · 2022
  Not checked
• On the measurement of skeletal muscle anisotropic permittivity property with a single cross-shaped needle insertion · 2022
  Not checked
• Tissue-Engineered Skeletal Muscle Models to Study Muscle Function, Plasticity, and Disease · 2021
  Not checked
• The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.